CBR 74 Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa (KRS 0000396972, NIP 1181800086) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. CBR 74 SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since September 23, 2011. CBR 74 SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ's most recently reported net revenue was 151.6 K PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - CBR 74
Identity
- Name
- CBR 74 Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa
- Legal form
- SPÓŁKA KOMANDYTOWA
- Founded
- September 23, 2011
- Registry status as of
- November 24, 2025
- Latest entry
- July 11, 2025
- Founding act
- 18.07.2011R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA, KANCELARIA NOTARIALNA W BABICACH NOWYCH UL.WARSZAWSKA 189, REPERTO…
Articles of association history (2)
- July 18, 2011: 18.07.2011R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA, KANCELARIA NOTARIALNA W BABICACH NOWYCH UL.WARSZAWSKA 189, REPERTORIUM A NR 1699/2011
- November 25, 2014: 25.11.2014 R., NOTARIUSZ MAŁGORZATA TOMCZYK-PERŁOWSKA PROWADZĄCA KANCELARIĘ NOTARIALNĄ W BABICACH NOWYCH (BABICE NOWE UL. WARSZAWSKA 189, 05-082 STARE BABICE) REP. A NR 2170/2014. ZMIENIONO: PAR. 2.1, PAR. 2.2, PAR. 3.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. WŁADYSŁAWA SIKORSKIEGO, 74, 05-082, JANÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2624, 20.8593approx.
Risk and payment profile - CBR 74
Credibility rating
75 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/15 yrs
Board changes
0
0/15 yrs
PKD changes
1
1/15 yrs
Name changes
1
1/15 yrs
Data from 15 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: B (75/100)
Trend: improving (+21.4 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2018–2024
Current: 178.3 K PLN
Safe: 115.9 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - CBR 74
Founded
September 23, 2011
14 years in operation
Legal form
SPÓŁKA KOMANDYTOWA
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
N/A
Shareholders
N/A
Board
N/A
Filed years
6 years
2018–2024 · profitable: 3/6
Registry entries
35
latest: July 11, 2025
Revenue
151.6 K PLN
2024
Net profit
75.5 K PLN
2024
Assets
561.8 K PLN
2024
Equity
560.9 K PLN
2024
EBITDA
127.7 K PLN
2024
Valuation
453.8 K PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - CBR 74.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
